Valiant Laboratories Limited (VALIANTLAB) announces its board's in-principle approval to explore restructuring options for achieving synergies.
Alembic Pharmaceuticals Limited (APLLTD) Q4 FY26 results show a 4% revenue growth, with significant gains in US Formulation and strong EBITDA margin.
Solara Active Pharma Sciences Limited (NSE: SOLARA) reports strong Q4’26 earnings with 40% YoY growth, driven by robust base business despite challenges in Ibuprofen segment.
Akums Drugs and Pharmaceuticals Limited (AKUMS) reports Q4 FY26 results with 9.7% revenue growth and 61.6% EBITDA surge.
Senores Pharmaceuticals Limited (SENORES) reports strong Q4 & FY26 results with revenue up 66% and PAT surge of 219%.
Cipla Limited (CIPLA) announced its Q4 FY26 results with robust growth in One India, North America, and One Africa segments.
Neuland Laboratories Limited reported a strong Q4FY26 with total income rising to Rs. 2053.1 crore, up 134.9%. EBITDA also surged.
Emcure Pharmaceuticals Limited shows robust Q4 FY26 results with 16.6% revenue growth and strategic portfolio expansion.
Emcure Pharmaceuticals Limited reports strong Q4 FY26 results with 16.7% revenue growth and 19.7% EBITDA margin.